Hospira Inc., a Pfizer company, is voluntarily recalling two lots of buprenorphine hydrochloride (HCl) injection Carpuject units. The recall was initiated due to the potential for incomplete crimp seals; one customer complaint has been received for one leaking unit.
In the event that impacted products are administered to a patient, there is a potential for an increased risk for lack of therapeutic effect and systemic infection that may result in the need for additional medical treatment,